MC2 Therapeutics Announces License, Supply and Commercialization Agreement for Wynzora® Cream in ASEAN Countries
POSTED: March 12, 2024
Copenhagen, March 12th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today an agreement with Hyphens Pharma Pte. ...
READ FULL ARTICLE >
MC2 Therapeutics to Present at Upcoming Conferences
POSTED: February 26, 2024
Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today that its leadership will attend and ...
READ FULL ARTICLE >